REPL EBITDA | REPLIMUNE GROUP, INC.

REPLIMUNE GROUP, INC. (REPL) EBITDA

2026-06-30: Basis Reported; EBITDA -$67.31M; Operating income (m); Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA -$72.57M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$71.07M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$83.49M; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2017-03-31 to 2026-06-30
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$67.31M	(m)	(m)	(m)	(m)	(m)	-$75.73M	(m)	$49.28M	$18.97M	(m)
2026-03-31	Reported	-$72.57M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-12-31	Reported	-$71.07M	(m)	(m)	(m)	(m)	(m)	-$65.95M*	(m)	$53.14M	(m)	-$311.00K
2025-09-30	Reported	-$83.49M	(m)	(m)	(m)	(m)	(m)	-$81.21M*	(m)	$57.88M	(m)	$0.00
2025-06-30	Reported	-$89.55M	(m)	(m)	(m)	(m)	(m)	-$77.02M	(m)	$57.84M	$32.58M	$0.00
2025-03-31	Reported	-$78.48M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-12-31	Reported	-$65.02M	(m)	(m)	(m)	(m)	(m)	-$50.71M*	(m)	$48.00M	(m)	$575.00K
2024-09-30	Reported	-$58.02M	(m)	(m)	(m)	(m)	(m)	-$38.64M*	(m)	$43.45M	(m)	$0.00
2024-06-30	Reported	-$56.63M	(m)	(m)	(m)	(m)	(m)	-$49.17M	(m)	$42.97M	(m)	$0.00
2024-03-31	Reported	-$58.05M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-12-31	Reported	-$55.84M	(m)	(m)	(m)	(m)	(m)	-$47.12M*	(m)	$42.85M	(m)	$473.00K
2023-09-30	Reported	-$63.13M	(m)	(m)	(m)	(m)	(m)	-$43.59M*	(m)	$49.10M	(m)	-$201.00K
2023-06-30	Reported	-$55.03M	(m)	(m)	(m)	(m)	$449.00K	-$48.59M	(m)	$40.44M	(m)	$201.00K
2023-03-31	Reported	-$52.47M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-12-31	Reported	-$40.95M*	-$41.63M	$682.00K*	(m)	(m)	$555.00K*	-$28.59M*	(m)	$30.26M	(m)	$0.00
2022-09-30	Reported	-$40.96M*	-$41.58M	$617.00K*	(m)	(m)	$396.00K*	-$33.21M*	(m)	$28.83M	(m)	$0.00
2022-06-30	Reported	-$40.26M	(m)	(m)	(m)	(m)	$1.07M	-$33.45M	(m)	$29.48M	(m)	$0.00
2022-03-31	Reported	-$31.44M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-12-31	Reported	-$29.15M*	-$29.70M	$548.00K*	(m)	(m)	$465.00K*	-$18.35M*	(m)	$19.35M	(m)	(m)
2021-09-30	Reported	-$28.71M*	-$29.25M	$532.00K*	(m)	(m)	$428.00K*	-$22.96M*	(m)	$19.90M	(m)	(m)
2021-06-30	Reported	-$26.86M	(m)	(m)	(m)	(m)	$291.00K	-$18.31M	(m)	$18.55M	(m)	(m)
2021-03-31	Reported	-$21.69M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$19.87M	(m)	(m)	(m)	(m)	$615.00K*	-$12.99M*	(m)	$14.32M	(m)	(m)
2020-09-30	Reported	-$19.24M	(m)	(m)	(m)	(m)	$75.00K*	-$17.18M*	(m)	$14.05M	(m)	(m)
2020-06-30	Reported	-$17.44M	(m)	(m)	(m)	(m)	$932.00K	-$15.09M	(m)	$12.16M	(m)	(m)
2020-03-31	Reported	-$16.04M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$16.56M	(m)	(m)	(m)	(m)	$4.06M*	-$15.73M*	(m)	$11.95M	(m)	(m)
2019-09-30	Reported	-$12.2M	(m)	(m)	(m)	(m)	$784.00K*	-$19.97M*	(m)	$8.17M	(m)	(m)
2019-06-30	Reported	-$10.87M	(m)	(m)	(m)	(m)	$362.00K	-$13.58M	(m)	$7.46M	(m)	(m)
2019-03-31	Reported	-$7.78M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$10.1M	(m)	(m)	(m)	(m)	$633.00K*	-$6.10M*	(m)	$7.86M	(m)	(m)
2018-09-30	Reported	-$7.07M	(m)	(m)	(m)	(m)	$3.00K*	-$6.38M*	(m)	$4.96M	(m)	(m)
2018-06-30	Reported	-$5.85M	(m)	(m)	(m)	(m)	$116.00K	-$6.86M	(m)	$3.94M	(m)	(m)
2018-03-31	Reported	-$7.04M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$4.7M	(m)	(m)	(m)	(m)	$6.00K*	-$2.69M*	(m)	$3.57M	(m)	(m)
2017-09-30	Reported	-$4.23M	(m)	(m)	(m)	(m)	$101.00K*	-$3.59M*	(m)	$3.15M	(m)	(m)
2017-06-30	Reported	-$3.15M	(m)	(m)	(m)	(m)	$33.00K	-$5.49M	(m)	$2.29M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-03-31	Reported	-$316.59M	(m)	(m)	(m)	(m)	(m)	-$280.34M	(m)	$221.18M	$98.73M	-$551.00K
2025-03-31	Reported	-$258.13M	(m)	(m)	(m)	(m)	(m)	-$192.25M	(m)	$189.45M	$72.18M	$468.00K
2024-03-31	Reported	-$232.12M	(m)	(m)	(m)	(m)	(m)	-$185.47M	(m)	$174.96M	(m)	$408.00K
2023-03-31	Reported	-$174.63M	(m)	(m)	(m)	(m)	$2.27M	-$128.05M	(m)	$126.53M	(m)	$288.00K
2022-03-31	Reported	-$116.17M	(m)	(m)	(m)	(m)	$2.34M	-$82.18M	(m)	$79.55M	(m)	$0.00
2021-03-31	Reported	-$78.24M	(m)	(m)	(m)	(m)	$2.39M	-$61.39M	(m)	$56.75M	(m)	$0.00
2020-03-31	Reported	-$55.67M	(m)	(m)	(m)	(m)	$6.54M	-$60.55M	(m)	$38.76M	(m)	$0.00
2019-03-31	Reported	-$30.8M	(m)	(m)	(m)	(m)	$2.60M	-$25.38M	(m)	$22.17M	(m)	$0.00
2018-03-31	Reported	-$19.12M	(m)	(m)	(m)	(m)	$136.00K	-$16.01M	(m)	$13.52M	(m)	$0.00
2017-03-31	Reported	-$9.53M	(m)	(m)	(m)	(m)	$238.00K	-$7.08M	(m)	$6.94M	(m)	$0.00

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Vor Biopharma Inc. (VOR)	United States	$1.091B	1.60
MeiraGTx Holdings plc (MGTX)	United States	$1.061B	16.10
Monte Rosa Therapeutics, Inc. (GLUE)	United States	$1.002B	-12.81
Cullinan Therapeutics, Inc. (CGEM)	United States	$0.993B	-5.72
Odyssey Therapeutics, Inc. (ODTX)	United States	$0.960B
Maze Therapeutics, Inc. (MAZE)	United States	$1.457B	-12.40
Inhibrx Biosciences, Inc. (INBX)	United States	$1.477B	-10.08
Sana Biotechnology, Inc. (SANA)	United States	$0.886B	-4.92
Candel Therapeutics, Inc. (CADL)	United States	$0.885B	-8.86
Attovia Therapeutics, Inc. (ATTO)	United States	$0.828B